Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...

Microscopic colitis is a lifelong condition that causes symptoms such as diarrhea and abdominal pain. It is a type of inflammatory bowel disease (IBD). While there is no cure for microscopic colitis, ...

Add Yahoo as a preferred source to see more of our stories on Google. “Debilitating digestive issues dominated my life because I couldn’t go longer than a half hour without going to the bathroom,” ...

These common supplements may actually be doing more harm than good.

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...

Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune suppressionThe study which compared MB310, a precision microbiome medicine, with ...

What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Researchers at örebro University have identified blood markers that can indicate who is at risk of developing ulcerative ...